PAVmed Inc. (NASDAQ: PAVM)

PAVmed Inc., a distinguished player in the healthcare industry, trades under the ticker symbol PAVM. The company is renowned for its focus on innovating, developing, acquiring, and commercializing novel products that cater to unmet needs in substantial market opportunities. Through its subsidiaries, such as Lucid Diagnostics Inc. and Veris Health Inc., PAVmed advances a pipeline of groundbreaking healthcare technologies.

Lucid Diagnostics, a majority-owned subsidiary, specializes in the development and commercialization of diagnostic tests for esophageal cancer and precancer detection. Its flagship product, EsoGuard, is a bisulfite-converted next-generation sequencing (NGS) DNA assay that accurately detects esophageal precancer and cancer in patients with chronic gastroesophageal reflux disease (GERD). EsoGuard is commercially available in the U.S. as a Laboratory Developed Test (LDT) conducted at Lucid's CLIA-certified laboratory.

PAVmed's EsoCheck, a noninvasive swallowable balloon capsule catheter device, collects surface esophageal cells for EsoGuard testing. This device has received both FDA 510(k) and CE Mark clearances, enabling it to detect esophageal precancer and cancer. Lucid is actively pursuing commercial insurer payment and coverage for EsoGuard and has secured out-of-network commercial insurance payments for the test.

PAVmed's market opportunity is considerable, with approximately 20,000 U.S. GERD patients projected to be diagnosed with esophageal adenocarcinoma (EAC) in 2023. Regrettably, over 80% of EAC patients succumb to the disease within five years of diagnosis. PAVmed believes that EsoGuard can prevent EAC deaths by detecting esophageal precancer and cancer in patients with chronic GERD.

PAVmed's competitive position is formidable, boasting a proprietary technology not yet available in the market. EsoGuard and EsoCheck have demonstrated remarkable accuracy in detecting esophageal precancer and cancer. PAVmed is diligently seeking regulatory clearance and reimbursement for these tests.

PAVmed's customers encompass primary care and gastroenterology physicians, as well as patients with chronic GERD. To expand access to EsoGuard, the company has established a network of test centers and is collaborating with healthcare systems and payors.

Veris Health, another majority-owned subsidiary, concentrates on digital health technology and has acquired Oncodisc, a digital health company offering groundbreaking tools for enhanced personalized cancer care through remote patient monitoring. Veris Health's platform aims to improve patient outcomes and reduce healthcare costs with remote monitoring and tailored treatment plans for cancer patients.

PAVmed's financial position is solid, exhibiting a cash balance of $18.16 million as of December 31, 2023. The company has also entered into a securities purchase agreement with Cantor to sell up to $50 million of its common stock at the market.